The Polycystic Kidney Disease Research Resource Consortium (PKD RRC) develops and shares investigative resources, reagents and expertise with the broader research community to accelerate innovation and discovery in the field of polycystic kidney disease. Explore our resources and core services to see how we can help you advance your research goals.
News, Events & Publications
@pkdresearch.bsky.social on Bluesky
Recent Publications
- Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients With Severe Lung Disease Carrying Previously Ineligible CFTR Mutations.
- Residual-Function and Splicing CFTR Variants Characterize False-Negative IRT Newborn Screening: A Ten-Year Single-Center Cohort From Türkiye.
- Corrigendum to "Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant" [J Cyst Fibros 24 (2025) 542-547].
- Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells.
- Atypical cranio-orbital perineural cysts in autosomal-dominant polycystic kidney disease.
- Corrigendum to "Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement" [Radiology Case Reports, volume 20, issue 4, 2025, pages 2093-2100].
- Development of a prediction model for aneurysmal events to guide imaging surveillance in autosomal dominant polycystic kidney disease.
- Adverse Events Associated with CFTR Modulator Therapy: Experience from a Tertiary Care Center.
- Analysis of CFTR mutation spectrum in Yugra region (Russian Federation).
- Mechanistic Insights into CFTR Potentiation by the Antimicrobial Peptide Esc(1-21): Direct Interaction with the NBD1-NBD2 Interface.
- Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions.
- Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment.
- Albumin overload reduces CFTR and V-ATPase expression and impairs albumin endocytosis and degradation in a renal proximal tubule cell line.
- PKD2-like proteins target Chlamydomonas PKD2 to distinct subciliary regions.
- A rapid automated segmentation method for total kidney volume measurement on unenhanced computed tomography in autosomal dominant polycystic kidney disease.
- Beyond Sequencing: Integrating MLPA Reveals Hidden Structural PKD2 Variants and Enhances Mutation Detection in a Highly Selected ADPKD Greek Cohort.
- Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania.
- Functional and Compositional Shifts in Lung and Gut Microbiota after One Year of Treatment with Highly Effective CFTR Modulators in Cystic Fibrosis.
- Heterozygous CFTR variants associated with low-phospholipid-associated cholelithiasis phenotypes expand hepatobiliary disorders spectrum.
- Cardiovascular-Kidney-Metabolic Syndrome in Autosomal Dominant Polycystic Kidney Disease.
- Elexacaftor/tezacaftor/ivacaftor improves CFTR function to near-normal levels in children with cystic fibrosis.
- CFTR correctors suppress Ca²⁺-cAMP signaling and cyst growth in primary cultures of ARPKD cholangiocytes.
- Autosomal dominant polycystic kidney disease in children and adolescents.
- Very-early-onset autosomal dominant polycystic kidney disease coexisting with congenital adrenal hyperplasia in a newborn: a case report.
- Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?".
- Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review.
